{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:04:35Z","timestamp":1790057075698,"version":"4.0.1"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite major therapeutic advances, multiple myeloma (MM) remains largely incurable. Moreover, side effects and toxicities of treatments compromise patients\u2019 quality of life. Dendritic cell (DC)-based cancer vaccines can induce long-term tumor-specific immune responses and are generally well tolerated. To improve the potency of this immunotherapeutic approach, researchers are now exploring combination strategies that integrate approved agents with DC-based vaccines. Proteasome inhibitors (PIs), including bortezomib and carfilzomib, are the standard of care for MM. PIs have been shown to induce so-called immunogenic cell death and could therefore be promising agents for combination approaches. However, careful selection of the optimal drug is mandatory, as off-target effects may also hamper the immune system, as previously shown for bortezomib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>By flow cytometry, we systematically evaluated the effects of the PI carfilzomib on the phenotype and expression of immune checkpoint molecules in monocyte-derived human DCs (moDCs) compared to bortezomib. Functional analyses included endocytosis, migration, cytokine secretion, and T cell stimulatory capacity in mixed lymphocyte reactions (MLRs), with and without PD-1 blockade. We assessed DC frequencies in peripheral blood and bone marrow of MM patients at diagnosis, during carfilzomib-based therapy, and in remission and further generated DCs using monocytes of carfilzomib-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Carfilzomib exposure did not compromise moDC characteristics, including phenotype, endocytosis, migration, and cytokine secretion, in vitro, whereas bortezomib-exposed moDCs differed significantly in several parameters. Carfilzomib modestly increased PD-L1 expression on moDCs and significantly reduced both their allostimulatory capacity and the IFN-\u03b3 production of cocultured T cells. PD-1 blockade with nivolumab fully reversed this effect and significantly enhanced it in MLR. We assessed reduced numbers of circulating DCs in MM patients at diagnosis, but numbers were comparable to those in healthy donors, patients receiving carfilzomib-based therapy and patients in remission. Furthermore, we could generate moDCs with a typical surface phenotype from monocytes of patients receiving carfilzomib-based therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings show that carfilzomib does not cause the broad impairment seen with bortezomib, and that the discrete deficit it does produce is reversible with PD-1 blockade. We hypothesize that carfilzomib is a more suitable proteasome inhibitor partner for DC-based immunotherapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1936021","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:39:35Z","timestamp":1790055575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Carfilzomib preserves dendritic cell phenotype and function compared with bortezomib"],"prefix":"10.3389","volume":"17","author":[{"given":"L.","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology and Cancer Immunology, Charit\u00e9 - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dahlfrancis","sequence":"additional","affiliation":[{"name":"Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen","place":["Tuebingen, Germany"]},{"name":"Department of Otolaryngology, Head and Neck Surgery, University Hospital Essen","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"D\u00f6rfel","sequence":"additional","affiliation":[{"name":"Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen","place":["Tuebingen, Germany"]},{"name":"Department of Medical Oncology, Hematology and Immunology, KRH Hospital Siloah","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Walz","sequence":"additional","affiliation":[{"name":"Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tuebingen","place":["Tuebingen, Germany"]},{"name":"German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tuebingen","place":["Tuebingen, Germany"]},{"name":"Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tuebingen","place":["Tuebingen, Germany"]},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Klatt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cancer Immunology, Charit\u00e9 - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin","place":["Berlin, Germany"]},{"name":"BIH Charit\u00e9 Clinician Scientist Program, Berlin Institute of Health (BIH) at Charit\u00e9 - Universitaetsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gr\u00fcnebach","sequence":"additional","affiliation":[{"name":"Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Rittig","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cancer Immunology, Charit\u00e9 - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin","place":["Berlin, Germany"]},{"name":"Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen","place":["Tuebingen, Germany"]},{"name":"BIH Charit\u00e9 Clinician Scientist Program, Berlin Institute of Health (BIH) at Charit\u00e9 - Universitaetsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20192","article-title":"Temporal patterns in US population-based patient survival among adults treated with chemotherapy and\/or immunotherapy for multiple myeloma, 2000-2020","volume":"207","author":"Dores","year":"2025","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2096363","article-title":"Trial watch: Dendritic cell (DC)-based immunotherapy for cancer","volume":"11","author":"Laureano","year":"2022","journal-title":"Oncoimmunology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4392","article-title":"Manipulating dendritic cell biology for the active immunotherapy of cancer","volume":"104","author":"O'Neill","year":"2004","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm9409","article-title":"Human dendritic cells in cancer","volume":"7","author":"Kvedaraite","year":"2022","journal-title":"Sci Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s12026-017-8931-1","article-title":"Dendritic cell-based immunotherapy: A basic review and recent advances","volume":"65","author":"Constantino","year":"2017","journal-title":"Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/bjh.13245","article-title":"Phase I\/II study exploring Immucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients","volume":"169","author":"Carmon","year":"2015","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1438-2","article-title":"Immunogenicity of dendritic cells pulsed with MAGE3, survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients","volume":"62","author":"Hobo","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005941","article-title":"Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant","volume":"6","author":"Chung","year":"2022","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2010-04-277137","article-title":"Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma","volume":"117","author":"Rosenblatt","year":"2011","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2012_057","article-title":"Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results","volume":"59","author":"Zahradova","year":"2012","journal-title":"Neoplasma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1871","article-title":"Role of immunotherapy in targeting the bone marrow microenvironment in multiple myeloma: An evolving therapeutic strategy","volume":"37","author":"Chung","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020904","article-title":"Dendritic cell-based immunotherapy in multiple myeloma: Challenges, opportunities, and future directions","volume":"23","author":"Verheye","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.953050","article-title":"Carfilzomib in multiple myeloma","volume":"14","author":"Andreu-Vieyra","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2018.03.002","article-title":"Next-generation proteasome inhibitors for cancer therapy","volume":"198","author":"Park","year":"2018","journal-title":"Transl Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.9b04147","article-title":"Sustained delivery of carfilzomib by tannic acid-based nanocapsules helps develop antitumor immunity","volume":"19","author":"Taha","year":"2019","journal-title":"Nano Lett"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201734","article-title":"Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency","volume":"9","author":"Li","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00050","article-title":"Immunogenic cell death and immunotherapy of multiple myeloma","volume":"7","author":"Serrano-Del Valle","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3494","article-title":"Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation","volume":"108","author":"Nencioni","year":"2006","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/397648","article-title":"Immunotherapy using dendritic cells against multiple myeloma: How to improve","volume":"2012","author":"Nguyen-Pham","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1984677","article-title":"Trial watch: Intratumoral immunotherapy","volume":"10","author":"Humeau","year":"2021","journal-title":"Oncoimmunology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cells11152351","article-title":"Cutting-edge: Preclinical and clinical development of the first approved LAG-3 inhibitor","volume":"11","author":"Chocarro","year":"2022","journal-title":"Cells"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00338-5","article-title":"The interaction of CD4(+) helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response","volume":"3","author":"Cohen","year":"2022","journal-title":"Nat Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic Malignancy: Preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v92.11.4238.423k16_4238_4247","article-title":"Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor","volume":"92","author":"Brossart","year":"1998","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.4.1109","article-title":"Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte\/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha","volume":"200","author":"Sallusto","year":"2018","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.4.1109","article-title":"Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte\/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha","volume":"179","author":"Sallusto","year":"1994","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.14","article-title":"Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini","volume":"6","author":"Kowalewski","year":"2016","journal-title":"Blood Cancer J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140432","article-title":"Expression of CD1a and type-1 polarization are dissociated in human monocyte-derived dendritic cells","volume":"10","author":"Mester","year":"2015","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03853.x","article-title":"CD1a expression defines an interleukin-12 producing population of human dendritic cells","volume":"155","author":"Cernadas","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000475","article-title":"Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10","volume":"186","author":"Dominguez-Soto","year":"2011","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.06.014","article-title":"CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions","volume":"21","author":"Ohl","year":"2004","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(02)02214-7","article-title":"CD83 on dendritic cells: More than just a marker for maturation","volume":"23","author":"Lechmann","year":"2002","journal-title":"Trends Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120466","article-title":"Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside","volume":"297","author":"Ghorbaninezhad","year":"2022","journal-title":"Life Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.04.019","article-title":"The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake","volume":"54","author":"de Mingo Pulido","year":"2021","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101888","article-title":"TIM-3 expression on dendritic cells in colorectal cancer","volume":"16","author":"Sakuma","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00262-011-1096-1","article-title":"The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors","volume":"61","author":"Schwarzbich","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of dendritic cells","volume":"18","author":"Banchereau","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01619","article-title":"Human bone marrow-derived myeloid dendritic cells show an immature transcriptional and functional profile compared to their peripheral blood counterparts and separate from slan+ non-classical monocytes","volume":"9","author":"van Leeuwen-Kerkhoff","year":"2018","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163717","article-title":"Plasmacytoid dendritic cells in patients with MGUS and multiple myeloma","volume":"10","author":"Knight","year":"2021","journal-title":"J Clin Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/198539","article-title":"Immunological dysregulation in multiple myeloma microenvironment","volume":"2014","author":"Romano","year":"2014","journal-title":"BioMed Res Int"},{"key":"B49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40425-019-0580-6","article-title":"The clinical application of cancer immunotherapy based on naturally circulating dendritic cells","volume":"7","author":"Bol","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300674","article-title":"Regulation of tumor dendritic cells by programmed cell death 1 pathways","volume":"212","author":"Knutson","year":"2024","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008148","article-title":"Intratumoral administration of the immunologic adjuvant As01(B) in combination with autologous Cd1c (Bdca-1)(+)\/Cd141 (Bdca-3)(+) myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma","volume":"12","author":"Tijtgat","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy Mrna-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (Keynote-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (Dc)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101367","article-title":"Immunomodulatory effect of proteasome inhibitors via the induction of immunogenic cell death in myeloma cells","volume":"16","author":"Matsushita","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2019.03.001","article-title":"The deubiquitinase inhibitor B-Ap15 and its effect on phenotype and function of monocyte-derived dendritic cells","volume":"21","author":"Schmidt","year":"2019","journal-title":"Neoplasia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2006.12.005","article-title":"Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib","volume":"68","author":"Subklewe","year":"2007","journal-title":"Hum Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2729","article-title":"Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients","volume":"15","author":"Verdijk","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"Pd-1 blockade by Ct-011, anti-Pd-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J Immunother"},{"key":"B61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00262-020-02654-0","article-title":"Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma","volume":"70","author":"Chu","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.semcdb.2018.02.015","article-title":"Dendritic cells as cancer therapeutics","volume":"86","author":"Bryant","year":"2019","journal-title":"Semin Cell Dev Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1575509","article-title":"Dendritic cells in multiple myeloma: From immune evasion to therapeutic potential","volume":"16","author":"Jordan","year":"2025","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3987","article-title":"Survivin dendritic cell vaccine safely induces immune responses and is associated with durable disease control after autologous transplant in patients with myeloma","volume":"29","author":"Freeman","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: Current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1038\/s41598-018-23943-w","article-title":"Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy","volume":"8","author":"Shinde","year":"2018","journal-title":"Sci Rep"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1395124","article-title":"Dendritic cell vaccine induces antigen-specific Cd8(+) T cells that are metabolically distinct from those of peptide vaccine and is well-combined with Pd-1 checkpoint blockade","volume":"7","author":"Nagaoka","year":"2018","journal-title":"Oncoimmunology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147509","article-title":"Enhancing dendritic cell cancer vaccination: The synergy of immune checkpoint inhibitors in combined therapies","volume":"25","author":"Zanotta","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000097","article-title":"Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma","volume":"38","author":"Nguyen-Pham","year":"2015","journal-title":"J Immunother"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (Keynote-185): A randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (Keynote-183): A randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"key":"B74","first-page":"1","article-title":"Influence of the novel proteasome inhibitor carfilzomib on human monocyte-derived dendritic cells","author":"Dahlfrancis","year":"2015","journal-title":"Oncol Res Treat"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1936021\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:39:37Z","timestamp":1790055577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1936021\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2026.1936021"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1936021","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1936021"}}